» Articles » PMID: 18294152

Acute Humoral Rejection of Renal Allografts in CCR5(-/-) Recipients

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2008 Feb 26
PMID 18294152
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing detection of acute humoral rejection (AHR) of renal allografts has generated the need for appropriate animal models to investigate underlying mechanisms. Murine recipients lacking the chemokine receptor CCR5 reject cardiac allografts with marked C3d deposition in the parenchymal capillaries and high serum donor-reactive antibody titers, features consistent with AHR. The rejection of MHC-mismatched renal allografts from A/J (H-2(a)) donors by B6.CCR5(-/-) (H-2(b)) recipients was investigated. A/J renal allografts survived longer than 100 days in wild-type C57BL/6 recipients with normal blood creatinine levels (28 +/- 7 micromol/L). All CCR5(-/-) recipients rejected renal allografts within 21 days posttransplant (mean 13.3 +/- 4 days) with elevated creatinine (90 +/- 31 micromol/L). The rejected allografts had neutrophil and macrophage margination and diffuse C3d deposition in peritubular capillaries, interstitial hemorrhage and edema, and glomerular fibrin deposition. Circulating donor-reactive antibody titers were 40-fold higher in B6.CCR5(-/-) versus wild-type recipients. Depletion of recipient CD8 T cells did not circumvent rejection of the renal allografts by CCR5-deficient recipients. In contrast, microMT(-/-)/CCR5(-/-) recipients, incapable of producing antibody, did not reject most renal allografts. Collectively, these results indicate the rapid rejection of renal allografts in CCR5(-/-) recipients with many histopathologic features observed during AHR of human renal allografts.

Citing Articles

Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5CD8 T Cells.

Zimmerer J, Chaudhari S, Koneru K, Han J, Abdel-Rasoul M, Uwase H Transplant Direct. 2025; 11(2):e1742.

PMID: 39802197 PMC: 11723704. DOI: 10.1097/TXD.0000000000001742.


Animal models for transplant immunology: bridging bench to bedside.

Kang M, Park H, Kim K, Choi D Clin Transplant Res. 2024; 38(4):354-376.

PMID: 39233453 PMC: 11732767. DOI: 10.4285/ctr.24.0029.


Antibody-Suppressor CXCR5+CD8+ T Cells Are More Potent Regulators of Humoral Alloimmunity after Kidney Transplant in Mice Compared to CD4+ Regulatory T Cells.

Han J, Zimmerer J, Zeng Q, Chaudhari S, Satoskar A, Abdel-Rasoul M J Immunol. 2024; 212(9):1504-1518.

PMID: 38517294 PMC: 11047759. DOI: 10.4049/jimmunol.2300289.


CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.

Han J, Zimmerer J, Zeng Q, Chaudhari S, Hart M, Satoskar A Transplantation. 2023; 108(3):679-692.

PMID: 37872660 PMC: 10922067. DOI: 10.1097/TP.0000000000004828.


CCR5 drives NK cell-associated airway damage in pulmonary ischemia-reperfusion injury.

Santos J, Wang P, Shemesh A, Liu F, Tsao T, Aguilar O JCI Insight. 2023; 8(21.

PMID: 37788115 PMC: 10721259. DOI: 10.1172/jci.insight.173716.